ICLR
ICON plc
NASDAQ · Healthcare · Medical - Diagnostics & Research · IE
$205.22
+0.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.2B | 8.3B | 8.3B | 8.1B | 7.7B |
| Cost of Revenue | 6.5B | 6.1B | 5.8B | 5.7B | 5.5B |
| Gross Profit | 1.7B | 2.2B | 2.4B | 2.4B | 2.2B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 771.5M | 780.1M | 728.3M | 776.4M | 778.8M |
| General & Admin Expense | 200.6M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 193.9M | 383.0M | 610.2M | 667.7M | 640.4M |
| Total Operating Expenses | 965.4M | 1.2B | 1.3B | 1.4B | 1.4B |
| Cost and Expenses | 7.5B | 7.2B | 7.2B | 7.2B | 6.9B |
| Operating Income (EBIT) | 779.3M | 1.0B | 1.1B | 956.2M | 795.2M |
| Non-Operating | |||||
| Interest Income | 12.1M | 7.1M | 8.6M | 5.0M | 2.3M |
| Interest Expense | 203.1M | 188.1M | 237.2M | 336.7M | 229.7M |
| Net Interest Income | (191.0M) | (181.0M) | (228.6M) | (331.7M) | (227.4M) |
| Other Non-Op Income/Expense | (245.1M) | (760.0M) | (228.6M) | (331.7M) | (230.5M) |
| Non-Operating Income (excl Interest) | (2.5M) | 571.9M | 22.4M | 20.7M | (2.3M) |
| EBT (Pre-Tax Income) | 534.2M | 252.5M | 869.2M | 624.1M | 564.7M |
| Income Tax Expense | 85.5M | 23.1M | 77.7M | 11.7M | 59.4M |
| Bottom Line | |||||
| Net Income | 448.7M | 229.3M | 791.5M | 612.3M | 505.3M |
| Earnings from Cont. Ops | 448.7M | 229.3M | 791.5M | 612.3M | 505.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 448.7M | 229.3M | 791.5M | 612.3M | 505.3M |
| Per Share | |||||
| Basic EPS | $5.85 | $2.92 | $9.60 | $7.46 | $6.20 |
| Diluted EPS | $5.81 | $2.90 | $9.53 | $7.40 | $6.13 |
| Revenue Per Share | $107.04 | $105.21 | $100.40 | $98.90 | $94.95 |
| Shares | |||||
| Basic Shares Outstanding | 76.9M | 78.4M | 82.5M | 82.1M | 81.5M |
| Diluted Shares Outstanding | 77.4M | 79.0M | 83.0M | 82.7M | 82.5M |
| Profitability Metrics | |||||
| EBITDA | 1.4B | 823.6M | 1.6B | 1.5B | 1.4B |
| D&A | 588.2M | 383.0M | 488.5M | 586.0M | 569.5M |
| EBIT | 781.7M | 440.6M | 1.1B | 935.5M | 797.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026